{"title": "Virus strain of a mild COVID-19 patient in Hangzhou representing a new trend in SARS-CoV-2 evolution related to Furin cleavage site", "doi": "10.1101/2020.03.10.20033944", "citation_id": "2020.03.10.20033944v2", "date": "2020-03-17", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.10.20033944", "abstract": "<p>We found, in our 788 confirmed COVID-19 patients, the decreased rate of severe/critical type, increased liver/kidney damage and prolonged period of nuclear acid positivity during virus dissemination, when compared with Wuhan. To investigate the underlining mechanism, we isolated one strain of SARS- CoV-2 (ZJ01) in mild COVID-19 patient and found the existence of 35 specific gene mutation by gene alignment. Further phylogenetic analysis and RSCU heat map results suggested that ZJ01 may be a potential evolutionary branch of SARS-CoV-2. We classified 54 strains of viruses worldwide (C/T type) based on the base (C or T) at positions 8824 and 28247. ZJ01 were both T at these two sites, becoming the only TT type currently identified in the world. The prediction of Furin cleavage site (FCS) and the sequence alignment of virus family indicated that FCS may be an important site of coronavirus evolution. ZJ01 had mutations near FCS (F1-2), which caused changes in the structure and the electrostatic distribution of the S protein surface, further affecting the binding capacity of Furin. Single cell sequencing and ACE2-Furin co-expression results confirmed that Furin level was higher in the whole body, especially in glands, liver, kidney and colon while FCS may help SARS-CoV-2 infect these organs. The evolutionary pattern of SARS-CoV-2 towards FCS formation may result in its clinical symptom becoming closer to HKU-1 and OC43 (the source of FCS sequence-PRRA) caused influenza, further showing potential in differentiating into mild COVID-19 subtypes.</p>", "twitter_description": "We found, in our 788 confirmed COVID-19 patients, the decreased rate of severe/critical type, increased liver/kidney damage and prolonged period of nuclear acid positivity during virus dissemination, when compared with Wuhan. To investigate the underlining mechanism, we isolated one strain of SARS- CoV-2 (ZJ01) in mild COVID-19 patient and found the existence of 35 specific gene mutation by gene alignment. Further phylogenetic analysis and RSCU heat map results suggested that ZJ01 may be a potential evolutionary branch of SARS-CoV-2. We classified 54 strains of viruses worldwide (C/T type) based on the base (C or T) at positions 8824 and 28247. ZJ01 were both T at these two sites, becoming the only TT type currently identified in the world. The prediction of Furin cleavage site (FCS) and the sequence alignment of virus family indicated that FCS may be an important site of coronavirus evolution. ZJ01 had mutations near FCS (F1-2), which caused changes in the structure and the electrostatic distribution of the S protein surface, further affecting the binding capacity of Furin. Single cell sequencing and ACE2-Furin co-expression results confirmed that Furin level was higher in the whole body, especially in glands, liver, kidney and colon while FCS may help SARS-CoV-2 infect these organs. The evolutionary pattern of SARS-CoV-2 towards FCS formation may result in its clinical symptom becoming closer to HKU-1 and OC43 (the source of FCS sequence-PRRA) caused influenza, further showing potential in differentiating into mild COVID-19 subtypes.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis research was supported by the National Key Program for Infectious Diseases of China (2017ZX10202202)\uff0cthe National Natural Science Foundation of China (No. 81770574, 81870080), the National Key R&D Program of China, Stem Cell and Translation Research (2018YFA0109300) and Zhejiang Province Science Foundation for Distinguished Young Scholars (LR19H080001)\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAnyone can share this material, provided it remains unaltered in any way, this is not done for commercial purposes, and the original authors are credited and cited.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.10.20033944v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.10.20033944v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.10.20033944v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/17/2020.03.10.20033944.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.10.20033944v2", "access_rights": "restricted", "authors": ["Jin Xi", "Kangli Xu", "Penglei Jiang", "Jiangshan Lian", "Shaorui Hao", "Hongyu Jia", "Hangping Yao", "Yimin Zhang", "Ruoheng Zheng", "Dong Chen", "Jinmei Yao", "Jianhua Hu", "Jianguo Gao", "Jian Shen", "Liang Wen", "Yue Ren", "Guodong Yu", "Xiaoyan Wang", "Yingfeng Lu", "Xiaopeng Yu", "Liang Yu", "Dairong Xiang", "Lin Zheng", "Nanping Wu", "Xiangyun Lu", "Linfang Cheng", "Fumin Liu", "Haibo Wu", "Changzhong Jin", "Xiaofeng Yang", "Pengxu Qian", "Yunqing Qiu", "Jifang Sheng", "Tingbo Liang", "Lanjuan Li", "Yida Yang"]}